Physician profile
Amanda B Hendrix
NPI 1669513677
$4,836.46
in general payments reported to CMS, 2019-2025
14 companies · $886 in 2025
The $886 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $227 · 2021: $220 · 2022: $813 · 2023: $1,048 · 2024: $1,218 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,152.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,707.81 | 2019-2025 | Total30, Precision7, Dailies Total1 |
| Coopervision INC. | $1,232.39 | 2019-2025 | Myday Contact Lens |
| Bausch & Lomb Americas INC. | $848.02 | 2022-2025 | Infuse, Biotrue, Envista Aspire Iol |
| Biotissue Holdings INC. | $231.86 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $145.26 | 2020-2021 | |
| Oyster Point Pharma, INC. | $139.87 | 2022-2024 | Tyrvaya |
| New World Medical,INC. | $124.24 | 2023 | |
| Optos, INC. | $122.88 | 2019 | |
| Sun Pharmaceutical Industries INC. | $90.87 | 2022-2023 | Cequa |
| Dompe US, INC. | $84.22 | 2024 | Oxervate |
| Rxsight INC | $45.45 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Allergan, INC. | $30.69 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.23 | 2019 | |
| Shire North American Group INC | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hendrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.